Literature DB >> 3504722

Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.

P M Boonekamp1, C W Löwik, L J van der Wee-Pals, M L van Wijk-van Lennep, O L Bijvoet.   

Abstract

The amino-bisphosphonate APD is distinct from the bisphosphonates EHDP and Cl2MDP by a greater molar potency in vivo as inhibitor of osteoclastic bone resorption and in vitro by a pronounced inhibitory effect on the accession of osteoclast precursors to mineralized matrix. Dimethylation of the aminogroup, which increases the basic properties of this residue but precludes others, like the liability to glucuronidation or acetylation, increased the in vivo potency of this amino bisphosphonate, as well as its in vitro specificity for osteoclast-precursor accession, but decreased its cellular toxicity. The in vitro actions of dimethyl-APD were reversible with administration of PTH. It is concluded that the introduction of a basic residue in bisphosphonates may increase affinity for the specific sites on the mineralized matrix that are involved in directing the accession of precursors and their transformation into actively resorbing osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504722

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  19 in total

1.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

Authors:  G van der Pluijm; H Vloedgraven; E van Beek; L van der Wee-Pals; C Löwik; S Papapoulos
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Authors:  Sung-Bae Kim; Jung Shin Lee; Heung Tae Kim; Yong Hyuck Im; Tae Won Kim; Baek Yeol Ryoo; Yeon Hee Park; Joon Oh Park; Keunchil Park; Hitoshi Katoh; Minoru Yamamoto
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

3.  Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.

Authors:  P S Rawlinson; R H Green; A M Coggins; I T Boyle; B E Gibson
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

4.  Structural aspects of the effectiveness of bisphosphonates as competitive inhibitors of the plant vacuolar proton-pumping pyrophosphatase.

Authors:  R Gordon-Weeks; S Parmar; T G Davies; R A Leigh
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

Review 5.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

6.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

Review 7.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 9.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

10.  The effects of several diphosphonates on murine bone marrow proliferation.

Authors:  K A Richard; N D Staite
Journal:  Agents Actions       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.